Skip to main content
HLF logo

HLF · Herbalife Ltd. · Documents

Track HLF — free
$15.57 +0.00 (+0.00%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.63B
Shares
104.90M
Volume · Nov 19 973.02K Avg daily vol (3M) 1.57M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $5.04B up 0.9% 10-K filed Feb 18, 2026 Quarterly report FY2026 Q3 Revenue $1.35B up 6.0% 10-Q filed Nov 2, 2026 Latest results Sales rise 6.0% as adjusted EBITDA reaches $182.4 million 8-K filed Nov 2, 2026 Earnings call Q3 2026 earnings call Held Nov 2, 2026
2026
Nov 2
Earnings call
Net sales up 6% to $1.4 billion; full-year guidance raised

Herbalife's third-quarter net sales rose 6% to $1.4 billion, with adjusted EBITDA of $182 million and a 13.5% margin. The company raised its full-year reported net sales growth outlook to 4.9% to 5.9%.

5 source passages
Third quarter net sales were $1.4 billion, up 6% versus the third quarter of 2025 Adjusted EBITDA was $182 million, also above our guidance range of $160 million to $180 million. An adjusted EBITDA margin was 13.5%, up 70 basis points year-over-year. For the full year, we have raised our net sales guidance on both a reported and constant currency basis. We now expect reported net sales to increase 4.9% to 5.9% year-over-year Open the document at this passage
Nov 2
Current report 8-K
Sales rise 6.0% as adjusted EBITDA reaches $182.4 million

Herbalife reported third-quarter net sales of $1.35 billion, up 6.0%, and adjusted EBITDA of $182.4 million. Year-to-date operating cash flow reached $298.0 million, and a share repurchase program of up to $250 million over three years was authorized.

Financial results, Regulation FD disclosure
4 source passages
Herbalife reported third quarter 2026 net sales of $1.35 billion, up 6.0% year-over-year, including 160 basis points of foreign currency (“FX”) headwinds, and primarily driven by increased sales volume. Adjusted EBITDA^1^ of $182.4 million includes approximately $11.3 million of FX headwinds year-over-year, with adjusted EBITDA^1^ margin of 13.5%, up 70 basis points versus the third quarter of 2025. Year-to-date net cash provided by operating activities of $298.0 million; capital expenditures of $40.7 million Board authorized new share repurchase program of up to $250 million over three years Open the document at this passage
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Nine-month net income falls 33.9% to $94.4 million

Herbalife's nine-month net income fell 33.9% to $94.4 million, mainly due to a $94.6 million loss on debt extinguishment, while net sales rose 6.4% to $3,994.2 million.

Revenue $1.35B ▲ 6.0% Net income $58.8M ▲ 36.1% Diluted EPS $0.55 ▲ 31.0%
Read from the MD&A section
5 source passages
Net income attributable to Herbalife was $58.8 million, or $0.55 per diluted share, and $94.4 million, or $0.88 per diluted share, for the three and nine months ended September 30, 2026, respectively. Net income attributable to Herbalife increased $15.6 million, or 36.1%, and decreased $48.5 million, or 33.9%, for the three and nine months ended September 30, 2026, respectively, as compared to the same periods in 2025. The decrease in net income attributable to Herbalife for the nine months ended September 30, 2026 was mainly due to $94.6 million of loss on extinguishment of debt related to our April 2026 debt refinancing Net sales were $1,350.2 million and $3,994.2 million for the three and nine months ended September 30, 2026, respectively. Net sales increased $76.5 million, or 6.0%, and $239.7 million, or 6.4%, for the three and nine months ended September 30, 2026, respectively, as compared to the same periods in 2025. Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.33B ▲ 5.4% Net loss $26.3M Diluted EPS -$0.25
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $1.32B ▲ 7.8% Net income $61.9M ▲ 22.8% Diluted EPS $0.57 ▲ 16.3%
Apr 16
Current report 8-K Events of Apr 15
Other events AI summary on its way
Mar 17
Proxy statement DEF 14A Meeting Apr 30, 2026
Proxy statement AI summary on its way
Feb 18
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $5.04B ▲ 0.9% Net income $228.3M ▼ 10.2% Diluted EPS $2.20 ▼ 12.0%
2025
Nov 5
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $1.27B ▲ 2.7% Net income $43.2M ▼ 8.9% Diluted EPS $0.42 ▼ 8.7%
Aug 6
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $1.26B ▼ 1.7% Net income $49.3M ▲ 948.9% Diluted EPS $0.48 ▲ 860.0%
Apr 30
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $1.22B ▼ 3.4% Net income $50.4M ▲ 107.4% Diluted EPS $0.49 ▲ 104.2%
Feb 19
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $4.99B ▼ 1.4% Net income $254.3M ▲ 78.8% Diluted EPS $2.50 ▲ 76.1%
2024
Oct 30
Quarterly report 10-Q FY2024 Q3, ended Sep 30
Quarterly report for FY2024 Q3
Revenue $1.24B ▼ 3.2% Net income $47.4M ▲ 10.7% Diluted EPS $0.46 ▲ 7.0%
Jul 31
Quarterly report 10-Q FY2024 Q2, ended Jun 30
Quarterly report for FY2024 Q2
Revenue $1.28B ▼ 2.5% Net income $4.7M ▼ 92.2% Diluted EPS $0.05 ▼ 91.7%
Showing 1–50 of 155 documents
Key facts CIK 1180262 CUSIP G4412G101 13F (30d) 260 filings 239 filers Visit website Investor relations